Kieron Dunleavy, MD, from the National Cancer Institute, Bethesda, MD, discusses treatment options in diffuse large B-cell lymphoma at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Vancouver, BC, Canada. The standard treatment for patients with diffuse large B-cell lymphoma is R-CHOP chemotherapy. There has been research into other treatments, such as R-CVP chemotherapy, however, none of these have been found more appropriate than R-CHOP, due to toxicity. Therefore, there needs to be further research to find other lymphoma treatments, and to determine which subgroups would benefit the most. This video was supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) through an unrestricted educational grant to Magdalen Medical Publishing. The company had no influence on the production of this content.